RDY DR REDDYS LABORATORIES LTD IFRS Annual reports only
Pharmaceutical Preparations · NYSE · SEC CIK 1135951 · Reporting currency INR · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: INR | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | 325.54B | 279.16B |
| Cost of revenue | 135.11B | 115.56B |
| Gross profit | 190.43B | 163.61B |
| R&D expense | 27.38B | 22.87B |
| SG&A expense | 93.87B | 77.20B |
| Operating income | 71.84B | 67.73B |
| Interest expense | 2.83B | 1.71B |
| Pretax income | 76.78B | 71.87B |
| Income tax | 19.54B | 16.19B |
| Net income | 56.54B | 55.68B |
| EBITDA | 88.90B | 82.57B |
| EPS (basic) | 67.88 | 66.93 |
| EPS (diluted) | 67.78 | 66.80 |
| Dividends declared per share | 40.00 | 40.00 |
| Weighted avg. shares (diluted) | 834.18M | 833.54M |
| Banking | ||
| Net interest income | -152.00M | 567.00M |
| Balance sheet | ||
| Cash & equivalents | 14.65B | 7.11B |
| Short-term investments | 43.25B | 74.36B |
| Receivables | 90.42B | 80.30B |
| Inventory | 71.08B | 63.55B |
| Current assets | 250.11B | 248.05B |
| PP&E, netmay include right-of-use assets (IFRS) | 97.76B | 76.89B |
| Goodwill | 11.81B | 4.25B |
| Intangibles | 96.80B | 36.95B |
| Total assets | 492.99B | 387.52B |
| Current liabilities | 130.39B | 96.04B |
| Short-term debt | 38.05B | 12.72B |
| Long-term debt | 7.86B | 5.99B |
| Total debt | 45.91B | 18.71B |
| Total liabilities | 155.82B | 106.97B |
| Shareholders' equity | 333.39B | 280.55B |
| Net debt | 31.25B | 11.61B |
| Shares outstanding | 832.64M | 830.78M |
| Cash flow statement | ||
| Operating cash flow | 46.43B | 45.43B |
| Capital expenditure | 27.50B | 16.40B |
| Free cash flow | 18.92B | 29.03B |
| Investing cash flow | -58.08B | -40.28B |
| Financing cash flow | 18.91B | -3.76B |
| Depreciation & amortization | 17.06B | 14.84B |
| Stock-based compensation | 424.00M | 407.00M |
| Dividends paid | 6.66B | 6.65B |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, INR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.